25 May 2017 | News
Jubilant is the second largest producer of Vitamin B3 globally
Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced a price increase of up to 15% for its Vitamin B3 (Niacin & Niacinamide) with immediate effect, for non-contract customers and wherever existing contracts permit. This is further to the price increase of up to 15% announced in December 2016.
Jubilant is the second largest producer of Vitamin B3 globally. The Vitamin B3 business is part of our Life Science Ingredients (LSI) segment, which offers a broad portfolio of high quality ingredients that find application in wide range of industries.
The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada.
The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA.
Jubilant Life Sciences has a team of around 6,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally.